IMMUCELL CORP /DE/ — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
ImmuCell reported Q2 2026 net income of $1.8M ($0.20/diluted share) on product sales of $7.2M (up 11.5% YoY), though gross margin declined to 33.9% from 43.7% due to low manufacturing volumes and a quality issue. A $2M one-time legal settlement from former CMO contributed materially to results. The company authorized a two-phase $8M capacity expansion ($3.5M first phase, $4.5M second phase) to triple manufacturing capacity by end-2027, to be funded from cash on hand ($8.9M as of June 30, 2026) and operations.
Why this rating
Revenue growth and market share gains are encouraging; the $8M capex commitment (16% of market cap) is material but manageable given $8.9M cash and positive operating cash flow ($6.6M YTD). One-time settlement masks underlying profitability. Moderate trajectory relevance given small scale and execution risk.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.